Clinical Trials Logo

Filter by:
NCT ID: NCT04124965 Completed - Clinical trials for Generalized Myasthenia Gravis

A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis

Start date: October 29, 2019
Phase: Phase 3
Study type: Interventional

The purpose of the MycarinGstudy is to evaluate the long-term safety, tolerability and long-term efficacy of rozanolixizumab in study participants with generalized myasthenia gravis (MG).

NCT ID: NCT04121520 Completed - Portal Hypertension Clinical Trials

Perioperative Care of HVPG Measurement (CHESS1904): An International Multicenter Survey

Start date: October 16, 2019
Phase:
Study type: Observational

Hepatic venous pressure gradient (HVPG) is an invasive test and requires technical skills of the operator and specialized instruments. HVPG measurement and anesthesia can cause stress responses in the body, which in turn lead to inflammatory response and immune function suppression. Thus, the perioperative care for patients undergoing HVPG measurement is crucial. This research trial studies comprehensive patient and medical worker questionnaires in predicting complications in patients with cirrhosis undergoing HVPG measurement. Comprehensive patient and medical worker questionnaires may help identify complications, such as the need for assistance in taking medication, decreased mobility and released tension that may improve outcomes.

NCT ID: NCT04118127 Completed - Schizophrenia Clinical Trials

A Clinical Pharmacology Trial of Brexpiprazole Once-weekly (QW) Formulation Administered as Single and Multiple Oral Doses

Start date: October 17, 2019
Phase: Phase 1
Study type: Interventional

To evaluate the pharmacokinetics (PK), tolerability, and safety of brexpiprazole QW formulation administered as single and multiple doses in patients with schizophrenia.

NCT ID: NCT04117113 Completed - E. Coli Infection Clinical Trials

Study to Collect Information About Invasive Disease Caused by Extraintestinal Pathogenic Escherichia Coli-2 (EXPECT-2)

EXPECT-2
Start date: October 22, 2019
Phase:
Study type: Observational

The purpose of this study is to collect information from study participants who are hospitalized with an invasive disease caused by Extraintestinal pathogenic E. coli (ExPEC). This information will be used to support the development of a new vaccine to prevent Extraintestinal pathogenic Escherichia coli (ExPEC). E. coli bacteria are a leading cause of serious infections. Especially adults older than 60 years have a higher risk of developing such infections. To date, there is no vaccine available to prevent E. coli infections. To support the development of a vaccine, more information about E. coli infections is first needed. This information will be collected in the current study, such as: - Medical information such as medical history, diagnosis, duration of hospitalization - Treatment and outcome of the Extraintestinal pathogenic Escherichia coli (ExPEC) - Laboratory information

NCT ID: NCT04115293 Completed - Clinical trials for Myasthenia Gravis, Generalized

Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis

RAISE
Start date: September 17, 2019
Phase: Phase 3
Study type: Interventional

The RAISE study is a multicenter, randomized, double-blind, placebo controlled study to confirm the efficacy, safety, and tolerability of zilucoplan in subjects with generalized Myasthenia Gravis. Subjects will be randomized in a 1:1 ratio to receive daily SC doses of 0.3 mg/kg zilucoplan or placebo for 12 weeks.

NCT ID: NCT04112303 Completed - Clinical trials for Hepatitis C Virus Infection

Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis

Start date: October 16, 2019
Phase: Phase 3
Study type: Interventional

The primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of therapy with sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) in adults with chronic hepatitis C virus (HCV) infection and compensated cirrhosis.

NCT ID: NCT04110054 Completed - Chronic Cough Clinical Trials

Evaluation of S-600918 in Adults With Refractory Chronic Cough

Start date: February 13, 2020
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to determine the optimal dose of S-600918 in patients with refractory chronic cough by evaluating the change from baseline in 24-hour cough frequency (coughs per hour) with S-600918 compared with placebo.

NCT ID: NCT04109313 Completed - Clinical trials for Chronic Spontaneous Urticaria

An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of LOU064 in Subjects With CSU

Start date: October 24, 2019
Phase: Phase 2
Study type: Interventional

The main objective to assess the long-term safety and tolerability of LOU064 in patients with chronic spontaneous urticaria (CSU) who have participated in study CLOU064A2201 (NCT03926611)

NCT ID: NCT04108351 Completed - Clinical trials for Healthy Participants

Development and Validation of a Driving Simulator for Evaluating the Residual Effects of Drugs on Driving Performance - Sensitivity Analysis Using Zopiclone as a Positive Control

Start date: October 7, 2019
Phase: N/A
Study type: Interventional

The purpose of this study is to confirm of assay sensitivity of Driving Simulator by positive control

NCT ID: NCT04097574 Completed - Bowel Disease Clinical Trials

Study of NPO-13 During Colonoscopy

Start date: August 26, 2019
Phase: Phase 2
Study type: Interventional

This study will investigate the safety, efficacy and dose-response of NPO-13 in subjects with moderate to severe colonic spasm during colonoscopy. An intraluminal spraying of NPO-13 dosed up to twice into ascending or sigmoid colon. The colonic spasm will be assessed by an independent committee using recorded video images. The study consists of a screening visit window, 1-day treatment phase and 1-week follow-up phase.